Akari Therapeutics closed a private placement financing with existing investors, Akari Chairman Dr. Ray Prudo and Director Samir R. Patel, M.D., on December 29, 2023, resulting in gross proceeds of approximately $2M. In connection with the financing, Akari issued 947,868 unregistered American Depository Shares, each representing 2,000 of the company’s ordinary shares, at a purchase price of $2.11 per ADS. Paulson Investment Company, LLC acted as the exclusive placement agent for this financing.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AKTX:
- Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing
- Akari Therapeutics to Present at Biotech Showcase 2024
- Akari Therapeutics appoints Samir Patel to board of directors
- Akari Therapeutics presents poster on progress on PASylated-nomacopan
